SU2C-CRI-MRA clinical trial with the anti-PD-1 antibody nivolumab and the anti-CTLA4 antibody nivolumab in patients with advanced melanoma. (Trial title: “PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) - Stand Up To Cancer

Blog

Posted October 14, 2019

SU2C-CRI-MRA clinical trial with the anti-PD-1 antibody nivolumab and the anti-CTLA4 antibody nivolumab in patients with advanced melanoma. (Trial title: “PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1)

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.